4D Molecular Therapeutics Inc
FDMT
Market Cap$1.33B
Close$
$-9.79
138.6% downside
Current Fair Value
138.6% downsideOvervalued by 138.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.33 Billion |
|---|---|
| Enterprise Value | $813.94 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.42 |
| Beta | 0.89 |
| Outstanding Shares | 51,703,412 |
| Avg 30 Day Volume | 431,415 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -12.68 |
|---|---|
| PEG | -97.78 |
| Price to Sales | - |
| Price to Book Ratio | 2.3 |
| Enterprise Value to Revenue | 39.8 |
| Enterprise Value to EBIT | -6.73 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
ESG Score
No data
About 4D Molecular Therapeutics Inc
83 employees4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power o...